Research Use Only. KIRhub outputs are computational research artifacts. They are not validated for clinical decision-making, diagnosis, or treatment.

← Cohorts · breast-umap@18

SRR8518288

— · A

71d6ec93-ef17-57f4-99ee-4a63d1dbc09f

Score in workbench →

Clinical attributes

From the source cohort, normalized into canonical keys plus the project's native columns.

cancer_type
—
cancer_type_detailed
—
subtype
A
subtype
A

GSVA pathway preview (50 Hallmark scores)

MeasuredDerivedReference

Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.

Top 10 elevated

  • INTERFERON_GAMMA_RESPONSE+0.470
  • INTERFERON_ALPHA_RESPONSE+0.460
  • IL6_JAK_STAT3_SIGNALING+0.410
  • ALLOGRAFT_REJECTION+0.380
  • COMPLEMENT+0.330
  • UV_RESPONSE_DN+0.260
  • INFLAMMATORY_RESPONSE+0.250
  • IL2_STAT5_SIGNALING+0.230
  • KRAS_SIGNALING_UP+0.220
  • HEDGEHOG_SIGNALING+0.210

Top 10 suppressed

  • MYC_TARGETS_V2-0.650
  • E2F_TARGETS-0.590
  • MYC_TARGETS_V1-0.570
  • G2M_CHECKPOINT-0.520
  • MTORC1_SIGNALING-0.470
  • UNFOLDED_PROTEIN_RESPONSE-0.410
  • GLYCOLYSIS-0.390
  • SPERMATOGENESIS-0.380
  • OXIDATIVE_PHOSPHORYLATION-0.360
  • DNA_REPAIR-0.280

Patient twins — nearest pathway neighbors

MeasuredDerived

10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.

10 twins match this tumor's tissue · 0 come from a different tissue of origin

#SampleCancer typeSubtypecos similarity
1SRR8518166
breast-umap@18
—D0.920
2TCGA-86-A4P8-01A-11R-A24X-07
lung-landscapes@6
—cohortA10.910
3TCGA-86-8671-01A-11R-2403-07
lung-landscapes@6
—cohortMD20.896
4TCGA-97-A4M6-01A-11R-A24X-07
lung-landscapes@6
—cohortA10.888
5SRR8613709
breast-umap@18
—A0.888
6SRR6013477
lung-landscapes@6
—cohortMD20.888
720040019.LumA
breast-umap@18
—A0.881
8SRR26320092
bladder-landscape@3
——0.878
9ULC0428T_S51
lung-landscapes@6
—cohortA10.878
10SRR10899975
melanoma-umap@29
——0.876

Per-pathway drug coverage

ModeledCalibratedDerived

For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.

0 of 23 elevated pathways have at least one drug that meaningfully reverses them.

Pathway (elevated)tumor scoreBest drugreversal magnitude
INTERFERON_GAMMA_RESPONSE0.470Idelalisib— uncovered
INTERFERON_ALPHA_RESPONSE0.460Inavolisib— uncovered
IL6_JAK_STAT3_SIGNALING0.410Inavolisib— uncovered
ALLOGRAFT_REJECTION0.380Idelalisib— uncovered
COMPLEMENT0.330Inavolisib— uncovered
UV_RESPONSE_DN0.260Inavolisib— uncovered
INFLAMMATORY_RESPONSE0.250Idelalisib— uncovered
IL2_STAT5_SIGNALING0.230Idelalisib— uncovered
KRAS_SIGNALING_UP0.220Inavolisib— uncovered
HEDGEHOG_SIGNALING0.210Inavolisib— uncovered
ADIPOGENESIS0.200Inavolisib— uncovered
TNFA_SIGNALING_VIA_NFKB0.180Inavolisib— uncovered
TGF_BETA_SIGNALING0.140Inavolisib— uncovered
XENOBIOTIC_METABOLISM0.140Inavolisib— uncovered
MYOGENESIS0.130Inavolisib— uncovered
COAGULATION0.120Binimetinib— uncovered
APOPTOSIS0.090Idelalisib— uncovered
P53_PATHWAY0.090Idelalisib— uncovered
ANGIOGENESIS0.050Remibrutinib— uncovered
HEME_METABOLISM0.040Temsirolimus— uncovered